New York, August 29, 2024 - PRISM MarketView - OS Therapies (NYSE-A: OSTX), a leading biopharmaceutical company specializing in ADC and immunotherapy research, has announced a major milestone in its AOST-2121 clinical trial (NCT04974008) for OST-HER2. The trial, which targets recurred, resected osteosarcoma, has completed its final treatment dose for the last enrolled patient, marking the end of the treatment phase.
OST-HER2 is an innovative immunotherapeutic vaccine using a Listeria monocytogenes (Lm) vector, designed to prevent metastasis, delay recurrence, and increase survival in osteosarcoma patients. The trial involved 41 patients across 21 clinical sites in the U.S., with a focus on 12-month Event Free Survival (EFS) and 36-month Overall Survival (OS).
With the completion of the final patient’s treatment, OS Therapies is preparing to close all clinical sites, lock the database, and begin data analysis. Topline data, including EFS and interim 2-year OS results, are expected in Q4 2024.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities